The world is rapidly entering an era of profound aging, and cardiovascular disease (CVD), as the leading cause of health-related mortality, continues to drive growing prevention and treatment needs. According to the World Health Organization, cardiovascular diseases remain the foremost cause of death globally, accounting for approximately 27% of all fatalities in 2019, which translates to about 15.1 million lives lost each year.

 

Within this challenging landscape, Cardiac Troponin I (cTnI) has solidified its role as the "gold standard" biomarker for diagnosing myocardial injury. Its detection demand is exhibiting steady and robust growth, particularly in primary and secondary healthcare institutions, indicating a broad and stable market outlook globally.

 

Our product features:

✔ High-sensitivity detection performance

✔ Exceptional specificity

✔ ISO 13485 certified

Contact us at [email address] for orders.